UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 316

Sortiert nach

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

Journal of clinical oncology, 2008-04, Vol.26 (12), p.2013-2019

2008

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

Journal of clinical oncology, 2008-04, Vol.26 (12), p.2006-2012

2008

Link zum Volltext

Verfügbarkeit prüfen

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer

British journal of cancer, 2018-12, Vol.119 (12), p.1464-1470

2018

Link zum Volltext

Verfügbarkeit prüfen

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database

Journal of clinical oncology, 2015-01, Vol.33 (1), p.22-28

2015

Link zum Volltext

Verfügbarkeit prüfen

SOD3 improves the tumor response to chemotherapy by stabilizing endothelial HIF-2α

Nature communications, 2018-02, Vol.9 (1), p.575-18, Article 575

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer

Journal of clinical oncology, 2007-11, Vol.25 (33), p.5225-5232

2007

Link zum Volltext

Verfügbarkeit prüfen

XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2004-06, Vol.22 (11), p.2084-2091

2004

Link zum Volltext

Verfügbarkeit prüfen

First‐Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According to KRAS Status from a Spanish TTD Group Study

The oncologist (Dayton, Ohio), 2012-03, Vol.17 (3), p.339-345

2012

Link zum Volltext

Verfügbarkeit prüfen

Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?

World journal of gastroenterology : WJG, 2014-05, Vol.20 (20), p.6092-6101

2014

Link zum Volltext

Verfügbarkeit prüfen

Molecular Classification of Colorectal Cancer by microRNA Profiling: Correlation with the Consensus Molecular Subtypes (CMS) and Validation of miR-30b Targets

Cancers, 2022-10, Vol.14 (21), p.5175

2022

Link zum Volltext

Verfügbarkeit prüfen

Nasoethmoidal Intestinal‐Type Adenocarcinoma Treated with Cetuximab: Role of Liquid Biopsy and BEAMing in Predicting Response to Anti‐Epidermal Growth Factor Receptor Therapy

The oncologist (Dayton, Ohio), 2019-03, Vol.24 (3), p.293-300

2019

Link zum Volltext

Verfügbarkeit prüfen

Role of GALNT12 in the genetic predisposition to attenuated adenomatous polyposis syndrome

PloS one, 2017-11, Vol.12 (11), p.e0187312

2017

Link zum Volltext

Verfügbarkeit prüfen

Role of cetuximab in first-line treatment of metastatic colorectal cancer

World journal of gastroenterology : WJG, 2014-04, Vol.20 (15), p.4208-4219

Sotelo, Miguel Jhonatan

2014

Link zum Volltext

Verfügbarkeit prüfen

Continuing Single‐Agent Bevacizumab as Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in First‐Line Treatment of Metastatic Colorectal Cancer

The oncologist (Dayton, Ohio), 2012-11, Vol.17 (11), p.1426-1428

2012

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy for gastric cancer

World journal of gastroenterology : WJG, 2006-01, Vol.12 (2), p.204

2006

Link zum Volltext

Verfügbarkeit prüfen

Capillary Electrophoresis Analysis of Conventional Splicing Assays: IARC Analytical and Clinical Classification of 31 BRCA2 Genetic Variants

Human mutation, 2014-01, Vol.35 (1), p.53-57

2014

Link zum Volltext

Verfügbarkeit prüfen

Circulating Tumor Cells Following First Chemotherapy Cycle: An Early and Strong Predictor of Outcome in Patients With Metastatic Breast Cancer

The oncologist (Dayton, Ohio), 2013-08, Vol.18 (8), p.917-923

2013

Link zum Volltext

Verfügbarkeit prüfen

A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families

Breast cancer research and treatment, 2011-10, Vol.129 (3), p.939-946

2011

Link zum Volltext

Verfügbarkeit prüfen

Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease

Translational research : the journal of laboratory and clinical medicine, 2015-12, Vol.166 (6), p.783-787

2015

Link zum Volltext

Verfügbarkeit prüfen

Molecular Analysis of Colorectal Cancer Tumors from Patients with Mismatch Repair–Proficient Hereditary Nonpolyposis Colorectal Cancer Suggests Novel Carcinogenic Pathways

Clinical cancer research, 2007-10, Vol.13 (19), p.5729-5735

2007

Link zum Volltext

Verfügbarkeit prüfen

Reassessing the TARBP2 mutation rate in hereditary nonpolyposis colorectal cancer

Nature genetics, 2010-10, Vol.42 (10), p.817-818

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 316

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(274)
Mit Volltextzugriff
(297)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(186)
Science & Technology
(179)
Life Sciences & Biomedicine
(168)
Oncology
(145)
Female
(130)
Middle Aged
(102)
Male
(87)
Aged
(86)
Adult
(76)
Biological And Medical Sciences
(53)
Medical Sciences
(52)
Tumors
(51)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(48)
Colorectal Neoplasms - Drug Therapy
(47)
Chemotherapy
(39)
Colorectal Cancer
(39)
Mutation
(36)
Colorectal Neoplasms - Pathology
(35)
Prognosis
(34)
Aged, 80 And Over
(32)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer

First‐Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single‐Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database

SOD3 improves the tumor response to chemotherapy by stabilizing endothelial HIF-2α

Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial

XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer

Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First‐Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study

First‐Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According to KRAS Status from a Spanish TTD Group Study

Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?

Molecular Classification of Colorectal Cancer by microRNA Profiling: Correlation with the Consensus Molecular Subtypes (CMS) and Validation of miR-30b Targets

Nasoethmoidal Intestinal‐Type Adenocarcinoma Treated with Cetuximab: Role of Liquid Biopsy and BEAMing in Predicting Response to Anti‐Epidermal Growth Factor Receptor Therapy

Role of GALNT12 in the genetic predisposition to attenuated adenomatous polyposis syndrome

Role of cetuximab in first-line treatment of metastatic colorectal cancer

Continuing Single‐Agent Bevacizumab as Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in First‐Line Treatment of Metastatic Colorectal Cancer

Chemotherapy for gastric cancer

Capillary Electrophoresis Analysis of Conventional Splicing Assays: IARC Analytical and Clinical Classification of 31 BRCA2 Genetic Variants

Circulating Tumor Cells Following First Chemotherapy Cycle: An Early and Strong Predictor of Outcome in Patients With Metastatic Breast Cancer

A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families

Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease

Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study

Molecular Analysis of Colorectal Cancer Tumors from Patients with Mismatch Repair–Proficient Hereditary Nonpolyposis Colorectal Cancer Suggests Novel Carcinogenic Pathways

Reassessing the TARBP2 mutation rate in hereditary nonpolyposis colorectal cancer

Suchergebnisse filtern